Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.88)
# 59
Out of 5,141 analysts
34
Total ratings
76.67%
Success rate
51.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $12.20 | +14.75% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $13.08 | +129.36% | 2 | Jan 16, 2026 | |
| ERAS Erasca | Maintains: Overweight | $5 → $11 | $12.54 | -12.28% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $57.63 | +21.46% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.33 | +243.35% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $6.84 | +250.88% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $11.11 | +98.02% | 1 | Jan 7, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $11.78 | +120.71% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $100.50 | +27.36% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $15.94 | +31.74% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $101.83 | -26.35% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $21.07 | +70.86% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $15.48 | +132.56% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.06 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.64 | +203.03% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.71 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $64.11 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $18.12 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.87 | - | 1 | Oct 31, 2022 |
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $12.20
Upside: +14.75%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $13.08
Upside: +129.36%
Erasca
Jan 16, 2026
Maintains: Overweight
Price Target: $5 → $11
Current: $12.54
Upside: -12.28%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $57.63
Upside: +21.46%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.33
Upside: +243.35%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $6.84
Upside: +250.88%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $11.11
Upside: +98.02%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $11.78
Upside: +120.71%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $100.50
Upside: +27.36%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $15.94
Upside: +31.74%
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $101.83
Upside: -26.35%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $21.07
Upside: +70.86%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $15.48
Upside: +132.56%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.06
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.64
Upside: +203.03%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.71
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $64.11
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $18.12
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.87
Upside: -